Myriad Genetics reports Q3 adjusted EPS 6c, consensus 2c
Reports Q3 revenue $213M, consensus $210.73M. “During the third quarter of 2024, we grew revenue by 11%, compared to the third quarter of ...
Myriad Genetics Inc (MYGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Policy ...
Myriad Genetics Inc (MYGN) reports robust revenue growth and strategic initiatives despite facing policy changes impacting ...
Business Wire8h
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. (“Myriad” or “the Company”) ...
Myriad Genetics plummets 20% as UnitedHealth changes GeneSight coverage
Myriad Genetics (NASDAQ:MYGN) is down ~20% in Friday trading following reports that UnitedHealth Group (UNH) will no longer ...
Business Insider16h
Myriad Genetics Inc. Q3 Earnings Summary
(RTTNews) - Below are the earnings highlights for Myriad Genetics Inc. (MYGN): Earnings: -$22.1 million in Q3 vs. -$61.3 million in the same period last year. EPS: -$0.24 in Q3 vs. -$0.75 in the ...
Myriad: Q3 Earnings Snapshot
SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Myriad Genetics Inc. (MYGN) on Thursday reported a loss of $22.1 million in its third quarter. On a per-share basis, the Salt Lake City-based company said ...
bovnews3d
The Myriad Genetics, Inc. Rollercoaster: What’s Behind the Latest MYGN Stock Fluctuation?
On Friday, Myriad Genetics, Inc. (MYGN) stock saw a decline, ending the day at $17.99 which represents a decrease of $-3.97 or -18.08% from the prior close of $21.96. The stock opened at $20.04 and ...
Zacks.com on MSN1d
BIIB vs. MYGN: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Biogen Inc. (BIIB) and Myriad Genetics (MYGN). But which of these two stocks offers value investors ...
ETF Daily News3d
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives $28.91 Consensus PT from Analysts
Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) has earned a consensus recommendation of “Hold” from the twelve analysts that are currently covering the stock, Marketbeat.com reports.